1072833-69-2

Basic information

• Product Name: [(1R)-1-{2-[(2,5-difluorophenyl)formamido]acetamido}-3-methylbutyl]boronic acid
• Synonyms: [(1R)-1-{2-[(2,5-difluorophenyl)formamido]acetamido}-3-methylbutyl]boronic acid
• CAS NO: 1072833-69-2
• Molecular Weight: 328.124
• Mol File: 1072833-69-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: [(1R)-1-{2-[(2,5-difluorophenyl)formamido]acetamido}-3-methylbutyl]boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [(1R)-1-{2-[(2,5-difluorophenyl)formamido]acetamido}-3-methylbutyl]boronic acid(1072833-69-2)
• EPA Substance Registry System: [(1R)-1-{2-[(2,5-difluorophenyl)formamido]acetamido}-3-methylbutyl]boronic acid(1072833-69-2)

Safety Data

• Hazardous Substances Data: 1072833-69-2(Hazardous Substances Data)

Upstream product

• 84110-40-7 Dihydroxy-isobutyl-boran 
• 179324-86-8 (1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^2,6]decan-4-yl]butan-1-amine 
• 926191-26-6 2-[(2,5-difluorophenyl)formamido]acetic acid 

Relevant articles and documents

Borate compound and pharmaceutically acceptable salt thereof, and preparation method and application of boric acid ester compound and pharmaceutically acceptable salt thereof

The invention relates to a borate compound as shown in a formula (1), a pharmaceutically acceptable salt thereof, a preparation method and application thereof. The borate compound is novel in structure and has a proteasome inhibition function. The stability of the borate compound disclosed by the invention in a solution is far higher than that of Ixazomib. Especially when the pH is 1.2 and the pH is 6.8, the stability of the compound provided by the invention is more advantageous. Besides, microsome stability results show that the compound has good stability in five different liver microsomes, the half-life period of the microsomes of Ixazomib in cynomolgus monkeys is too long, the medicine is basically not metabolized, and serious toxicity can be caused. The compound can be used for preparing medicines for treating inflammation, immune-related diseases, cancers or hyperproliferative diseases and changing antigen peptides generated by proteasomes in organisms.

PROTEASOME INHIBITORS

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.